Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia

BACKGROUND: Levodopa-induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson’s disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosero, Yuri L., Bandres-Ciga, Sara, Ferwerda, Bart, Tocino, Maria T. P., Belloso, Dìaz R., Gómez-Garre, Pilar, Faouzi, Johann, Taba, Pille, Pavelka, Lukas, Marques, Tainà M., Gomes, Clarissa P. C., Kolodkin, Alexey, May, Patrick, Milanowski, Lukasz M, Wszolek, Zbigniew K., Uitti, Ryan J., Heutink, Peter, van Hilten, Jacobus J., Simon, David K., Eberly, Shirley, Alvarez, Ignacio, Krohn, Lynne, Yu, Eric, Freeman, Kathryn, Rudakou, Uladzislau, Ruskey, Jennifer A., Asayesh, Farnaz, Menéndez-Gonzàlez, Manuel, Pastor, Pau, Ross, Owen A., Krüger, Rejko, Corvol, Jean-Christophe, Koks, Sulev, Mir, Pablo, De Bie, Rob M.A., Iwaki, Hirotaka, Gan-Or, Ziv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543218/
https://www.ncbi.nlm.nih.gov/pubmed/37790572
http://dx.doi.org/10.1101/2023.08.28.23294610

Ejemplares similares

Ejemplares similares